SI0775704T1 - Crystalline hydrochloride of (R)-(-)-2-(N-(4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl)-aminomethyl)-chroman - Google Patents

Crystalline hydrochloride of (R)-(-)-2-(N-(4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl)-aminomethyl)-chroman

Info

Publication number
SI0775704T1
SI0775704T1 SI9630292T SI9630292T SI0775704T1 SI 0775704 T1 SI0775704 T1 SI 0775704T1 SI 9630292 T SI9630292 T SI 9630292T SI 9630292 T SI9630292 T SI 9630292T SI 0775704 T1 SI0775704 T1 SI 0775704T1
Authority
SI
Slovenia
Prior art keywords
dihydrobenzisothiazol
dioxido
chroman
aminomethyl
oxo
Prior art date
Application number
SI9630292T
Other languages
English (en)
Inventor
Alfons Dr Grunenberg
Oliver Dr Brehm
Michael Dr Conrad
Dietrich Dr Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SI0775704T1 publication Critical patent/SI0775704T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI9630292T 1995-11-22 1996-11-11 Crystalline hydrochloride of (R)-(-)-2-(N-(4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl)-aminomethyl)-chroman SI0775704T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
EP96118043A EP0775704B1 (de) 1995-11-22 1996-11-11 Kristallines Hydrochlorid von (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman

Publications (1)

Publication Number Publication Date
SI0775704T1 true SI0775704T1 (en) 2001-08-31

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630292T SI0775704T1 (en) 1995-11-22 1996-11-11 Crystalline hydrochloride of (R)-(-)-2-(N-(4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl)-aminomethyl)-chroman

Country Status (32)

Country Link
US (1) US5830908A (no)
EP (1) EP0775704B1 (no)
JP (1) JPH09143180A (no)
KR (1) KR970027079A (no)
CN (1) CN1086703C (no)
AR (1) AR004961A1 (no)
AT (1) ATE201872T1 (no)
AU (1) AU712922B2 (no)
BR (1) BR9605646A (no)
CA (1) CA2190700A1 (no)
CZ (1) CZ289730B6 (no)
DE (2) DE19543478A1 (no)
DK (1) DK0775704T3 (no)
EE (1) EE9600183A (no)
ES (1) ES2159342T3 (no)
GR (1) GR3036505T3 (no)
HU (1) HUP9603237A3 (no)
IL (1) IL119647A (no)
MX (1) MX9605741A (no)
MY (1) MY132473A (no)
NO (1) NO307340B1 (no)
NZ (1) NZ299780A (no)
PL (1) PL317090A1 (no)
PT (1) PT775704E (no)
RU (1) RU2181723C2 (no)
SG (1) SG44989A1 (no)
SI (1) SI0775704T1 (no)
SK (1) SK150096A3 (no)
TR (1) TR199600930A2 (no)
TW (1) TW449595B (no)
UA (1) UA45338C2 (no)
ZA (1) ZA969753B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
JPH09143180A (ja) 1997-06-03
DE19543478A1 (de) 1997-05-28
MY132473A (en) 2007-10-31
IL119647A0 (en) 1997-02-18
SG44989A1 (en) 1997-12-19
PT775704E (pt) 2001-09-28
MX9605741A (es) 1997-05-31
PL317090A1 (en) 1997-05-26
ES2159342T3 (es) 2001-10-01
DE59607040D1 (de) 2001-07-12
GR3036505T3 (en) 2001-11-30
HU9603237D0 (en) 1997-01-28
NO964950L (no) 1997-05-23
CN1086703C (zh) 2002-06-26
CN1152574A (zh) 1997-06-25
BR9605646A (pt) 1998-08-18
TR199600930A2 (tr) 1997-06-21
US5830908A (en) 1998-11-03
TW449595B (en) 2001-08-11
EE9600183A (et) 1997-06-16
UA45338C2 (uk) 2002-04-15
ATE201872T1 (de) 2001-06-15
CZ289730B6 (cs) 2002-03-13
EP0775704A1 (de) 1997-05-28
IL119647A (en) 1999-12-22
AU7177296A (en) 1997-05-29
HUP9603237A2 (hu) 1998-01-28
NO964950D0 (no) 1996-11-21
CA2190700A1 (en) 1997-05-23
KR970027079A (ko) 1997-06-24
AU712922B2 (en) 1999-11-18
EP0775704B1 (de) 2001-06-06
RU2181723C2 (ru) 2002-04-27
CZ342896A3 (en) 1997-06-11
NZ299780A (en) 1998-09-24
AR004961A1 (es) 1999-04-07
NO307340B1 (no) 2000-03-20
HUP9603237A3 (en) 1998-12-28
DK0775704T3 (da) 2001-07-23
SK150096A3 (en) 1997-08-06
ZA969753B (en) 1997-03-25

Similar Documents

Publication Publication Date Title
SI0775704T1 (en) Crystalline hydrochloride of (R)-(-)-2-(N-(4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl)-aminomethyl)-chroman
SG43787A1 (en) Novel paroxetine hydrochloride anhydrate
AU7493296A (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
NO306783B1 (no) Fremgangsmåte for fremstilling av 1-(2'-deoksy-2',2'-difluor-D-ribofuranosyl-4-aminopyrimidin-2-on)hydroklorid
NO2005009I1 (no) Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
DE69606721D1 (de) 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
PL334184A1 (en) Fungicidal compositions based on methyl n-(phenylacetyl)-n-(2,6-xylyl) alaninate
PL327136A1 (en) 1-(1,2-disubstituted)(condensed) derivatives of-4-(imidazol)-piperidine
ID21499A (id) Proses untuk memproduksi n-(4-fluorofenil)-n-(1-metiletil)-2-[(5-(trifluorometil)-1,3,4-tiadiazol-2-il)-oksi]-asetamida
AU1582097A (en) 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specificligands
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
PL330424A1 (en) Modified form of r(-)-n-(4,4-di (3-methylthien-2-yl) but-3-nyl) nipecotinic hydrochloride
NO20003145D0 (no) FremgangsmÕte for fremstilling av paroxetine-hydroklorid
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides
AU7492496A (en) Salts of N-(4-oxo-2-(1H-tetrazoyl-5-yl)-4H-1-benzopyran-8-yl)-4-(4-ph enylbutoxy)benzamide
NZ315363A (en) 1-[2-(2,3-dihydro-1h-inden-1-yl)ethyl]-4-(naphthalen-1-yl)piperazine derivatives, preparation thereof and therapeutical use thereof
AU740561C (en) Paroxetine hydrochloride anhydrate
LT96007A (en) Paroxetine hydrochloride anhydrate and process for preparing thereof
NO20012028L (no) Fremgangsmåte for fremstilling av 4-((2',5'-diamino-6'- halogenpyrimidin-4'-yl)amino)-cyclopent-2-enyl-metanoler
ZA952815B (en) Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2-carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine